Kisspeptin vs Lanreotide
Overview
Kisspeptin and Lanreotide are both hormonal peptides, but they differ in mechanism, dosing, and regulatory status.
This page compares Kisspeptin and Lanreotide across their primary use, typical dosing, reported benefits and side effects, and U.S. regulatory status. For the full monograph on either compound — mechanism of action, clinical research, and references — follow the article links.
Side-by-side comparison
| Kisspeptin | Lanreotide | |
|---|---|---|
| Category | Hormonal | Hormonal |
| Regulatory status (US) | Research use only | FDA approved |
| Typical dosage | 1-10 mcg | 60-120 mg |
| Frequency | as prescribed | every 4 weeks |
| Reported benefits | Fertility support, hormone balance, libido enhancement | suppression of excess growth hormone and IGF-1 in acromegaly, improved progression-free survival in GEP-NETs, reduction of carcinoid syndrome symptoms, inhibition of multiple GI and pancreatic hormones |
| Reported side effects | Generally safe in clinical use | diarrhea, cholelithiasis, abdominal pain, hyperglycemia, bradycardia, injection site reactions, nausea, hypertension, headache, thyroid function decreases |
Key differences
Primary use. Kisspeptin is categorised under Hormonal, while Lanreotide falls under Hormonal. Because they target a similar goal, they are common alternatives to weigh against each other.
Regulatory status. Kisspeptin: not FDA-approved; treated as a research compound. Lanreotide: FDA-approved.
Dosing. Kisspeptin is typically dosed at 1-10 mcg (as prescribed). Lanreotide is typically dosed at 60-120 mg (every 4 weeks).
Can you stack them?
Some protocols combine peptides, but stacking Kisspeptin and Lanreotide has not been validated for safety or efficacy in controlled trials. Combining compounds can change their effects and risks. Nothing here is medical advice — consult a qualified healthcare provider before starting or combining any protocol.
Frequently asked questions
- What is the difference between Kisspeptin and Lanreotide?
- Kisspeptin and Lanreotide are both hormonal peptides, but they differ in mechanism, dosing, and regulatory status. Kisspeptin is not FDA-approved; generally classified as a research compound, whereas Lanreotide is FDA-approved for one or more indications.
- What is Kisspeptin used for?
- Reproductive hormone regulator.
- What is Lanreotide used for?
- FDA-approved long-acting somatostatin analog for acromegaly, GEP-NETs, and carcinoid syndrome.
- Can you take Kisspeptin and Lanreotide together?
- Some users combine peptides within a single protocol, but stacking Kisspeptin and Lanreotide has not been established as safe or effective in controlled trials. Neither this comparison nor PeptideSciences101 is medical advice — consult a qualified healthcare provider before combining any compounds.
- Is Kisspeptin or Lanreotide FDA-approved?
- Kisspeptin is not FDA-approved; generally classified as a research compound. Lanreotide is FDA-approved for one or more indications.
Read the full articles
- Kisspeptin — full monograph: mechanism, research, dosing & references
- Lanreotide — full monograph: mechanism, research, dosing & references